Navigation Links
Frost & Sullivan Accolade for Ferring Pharmaceuticals
Date:3/25/2009

LONDON, March 25 /PRNewswire/ -- The 2008 Frost & Sullivan European Human Growth Hormone Competitive Strategy Leadership Award is presented to Ferring Pharmaceuticals. The award is in recognition of Ferring's initiatives in providing no-needle injection for human growth hormone (hGH). The company offers ZOMAJET 2 VISION and ZOMAJET VISION X, innovative no-needle delivery systems for its human growth hormone, ZOMACTON.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

These novel, no-needle delivery systems are poised to help Ferring to not only sustain its market share in the European growth hormones market, but also to expand its presence in the hGH market worldwide.

"Drug delivery systems provide strategic differentiation to successfully increase sales for companies established in the hGH market," notes Frost & Sullivan Research Analyst Prabakar Sampath. "Through its innovation in no-needle devices, and clinical evidence showing the high level of childrens' preference for no-needle hGH administration, Ferring has shown leadership in meeting the needs of the paediatric population in this therapy area. "

The majority of end users of hGH are children under the age of fifteen. Patient compliance is an issue for treatment with drugs that have to be administered on a daily basis. Frost & Sullivan's end user analysis suggests that over 30 per cent of children using traditional methods of injection are likely to stop using hGH due to the inconvenience caused. This poor compliance is attributed to 'needle-phobia' and pain caused while administering injections.

A strategic partnership with Antares has enabled Ferring to provide pioneering, no-needle delivery devices for ZOMACTON. Ferring launched the ZOMAJET 2 VISION in Europe in 2002. It was one of the early providers of no-needle systems for hGH, making it an ideal choice for drug administration among the paediatric population.

Ferring is strongly committed to increasing physician awareness. For over two decades, it has been sponsoring training programmes hosted by the European Society for Paediatric Endocrinology (ESPE). These programmes are aimed at promoting physician awareness of new trends and treatments in the endocrinology domain.

"The company also encourages discussions and interactions between older and younger paediatric endocrinologists," states Sampath. "The sizeable educational grant provided by Ferring for such training programmes reflects its commitment to ensuring quality medical education for young endocrinologists."

The Frost & Sullivan Award for Competitive Strategy Leadership is presented to the company whose competitive strategy has yielded significant gains in market share during the research period. Often, the recognised company has taken advantage of recent market changes that facilitate the introduction of never-before seen methods of capturing and solidifying market presence. Alternatively, the Award recipient may have executed an innovative strategy within the existing competitive landscape, empowering the company to overtake the competition. In either case, the company captures the attention of the competition, which quickly adjusts in order to protect its own market position. Frost & Sullivan analysts expect such innovations to produce lasting, precedent-setting trends in the industry.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, urology, infertility and obstetrics.

Ferring has its own operating subsidiaries in 45 countries and markets its products in more than 70 countries. To learn more about Ferring or our products please visit www.ferring.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Ciara Jamie Connolly, Senior Events & Promotions Executive EMEA,
    Best Practices, Frost & Sullivan, ciara.connolly@frost.com,
    P: 0044 (0) 207.915.7868, F: 0044 (0) 207.730.3343, www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Leveraging the Third Amendment Ruling the Risk Management Process: Frost & Sullivans Assessment of Regulations for Medical Imaging Equipment in Europe
2. Frost & Sullivan Honours Outstanding Achievements in Healthcare
3. Sentinelle Medical Receives Frost & Sullivan Excellence in Technology Award
4. Patients Remote(ly) Monitored: Ask Frost & Sullivan, What Is Driving the European Market
5. Frost & Sullivan Awards Philips Healthcare for Brilliance iCT 256 Slice and iCT SP 128 Slice CT Systems
6. Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan
7. Frost & Sullivan Commends Nycomed for Excellence in Product Differentiation Innovation
8. Frost & Sullivan Recognizes GE Healthcare for Strategic Leadership in Acquiring Dynamic Imaging to Grow Its Imaging Informatics Business
9. Frost & Sullivan Lauds Pioneer Surgical Technology for Development of Tissue Scaffold E-Matrix
10. Frost & Sullivan Recognises FUJIFILM Corporations Outstanding Product Quality Leadership
11. Frost & Sullivan Product Quality Accolade for KIBI Software Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , ... February 12, 2016 , ... The law firm ... and Evangeline Parishes. The purpose of these scholarships is to encourage applicants to ... individuals to seek employment within these two parishes. , “We have available jobs ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... ... 2016 , ... Vail knee specialist Robert LaPrade, MD, PhD was ... The list consists of physicians establishing, leading and partnering with ambulatory surgery centers across ... Ambulatory Surgery Center, also known as an ASC, is a modern health care facility ...
(Date:2/12/2016)... ... 2016 , ... For Coast Dental dentist Everet Lake, DDS, the smiles began ... Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event ... skills to help hundreds of uninsured and underinsured people receive much-needed dental care. ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
(Date:2/11/2016)... N.C. , Feb. 11, 2016 ... leading provider of custom manufacturing and development services ... expanded sterile fill-finish capabilities and capacity in its ... growth in demand has driven several recent investments. ... 2001 it had one filling line with small-scale ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
Breaking Medicine Technology: